Cargando…

Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center

Introduction: The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). Methods: Study participants were recruited from hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Skrzat-Klapaczyńska, Agata, Kowalska, Justyna Dominika, Paciorek, Marcin, Puła, Joanna, Bieńkowski, Carlo, Krogulec, Dominika, Stengiel, Jarosław, Pawełczyk, Agnieszka, Perlejewski, Karol, Osuch, Sylwia, Radkowski, Marek, Horban, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785047/
https://www.ncbi.nlm.nih.gov/pubmed/36560567
http://dx.doi.org/10.3390/vaccines10122158
_version_ 1784857957918310400
author Skrzat-Klapaczyńska, Agata
Kowalska, Justyna Dominika
Paciorek, Marcin
Puła, Joanna
Bieńkowski, Carlo
Krogulec, Dominika
Stengiel, Jarosław
Pawełczyk, Agnieszka
Perlejewski, Karol
Osuch, Sylwia
Radkowski, Marek
Horban, Andrzej
author_facet Skrzat-Klapaczyńska, Agata
Kowalska, Justyna Dominika
Paciorek, Marcin
Puła, Joanna
Bieńkowski, Carlo
Krogulec, Dominika
Stengiel, Jarosław
Pawełczyk, Agnieszka
Perlejewski, Karol
Osuch, Sylwia
Radkowski, Marek
Horban, Andrzej
author_sort Skrzat-Klapaczyńska, Agata
collection PubMed
description Introduction: The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). Methods: Study participants were recruited from hospital employees who received BNT162b2 vaccination at the Hospital for Infectious Diseases in Warsaw. Blood samples were collected before and after each vaccination dose. At each timepoint, the levels of anti-SARS CoV-2 IgM, anti-n SARS-CoV-2 IgG, and S-RBD antibodies were measured. Data on concomitant diseases and the vaccine’s adverse events (VAE) were collected after each vaccination dose. In the statistical analyses, non-parametric tests were used. Results: In total, 170 healthcare workers were included in the analysis. Their median age was 51 years (interquartile range (IQR): 41–60 years); most of them were women (n = 137, 80.6%) working in direct contact with patients (n = 137, 73.2%); and 46 (27.0%) had concomitant diseases. More than one fifth of subjects had COVID-19 before their first dose of vaccination (n = 38, 22.6%). In terms of immunological responses, our investigations showed a high level of efficacy for the BNT162b2 mRNA vaccination as measured by S-RBD antibody concentrations: these were positive in 100% of participants 14 days after the second dose of the vaccine. It was also observed that employees with high S-RBD antibodies (>=433 BAU/mL) were more likely to be COVID-19 convalescents before receiving the first vaccine dose (p < 0.001). Conclusion: The BNT162b2 vaccine is safe and effective among HCWs. Vaccine adverse events occurred, but serious events were not observed. Moreover, the BNT162b2 vaccine is effective against symptomatic and severe COVID-19—none of the workers that acquired a SARS-CoV-2 infection after vaccination required hospitalization or medical care. We also observed higher immunological responses among COVID-19 convalescents.
format Online
Article
Text
id pubmed-9785047
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97850472022-12-24 Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center Skrzat-Klapaczyńska, Agata Kowalska, Justyna Dominika Paciorek, Marcin Puła, Joanna Bieńkowski, Carlo Krogulec, Dominika Stengiel, Jarosław Pawełczyk, Agnieszka Perlejewski, Karol Osuch, Sylwia Radkowski, Marek Horban, Andrzej Vaccines (Basel) Article Introduction: The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). Methods: Study participants were recruited from hospital employees who received BNT162b2 vaccination at the Hospital for Infectious Diseases in Warsaw. Blood samples were collected before and after each vaccination dose. At each timepoint, the levels of anti-SARS CoV-2 IgM, anti-n SARS-CoV-2 IgG, and S-RBD antibodies were measured. Data on concomitant diseases and the vaccine’s adverse events (VAE) were collected after each vaccination dose. In the statistical analyses, non-parametric tests were used. Results: In total, 170 healthcare workers were included in the analysis. Their median age was 51 years (interquartile range (IQR): 41–60 years); most of them were women (n = 137, 80.6%) working in direct contact with patients (n = 137, 73.2%); and 46 (27.0%) had concomitant diseases. More than one fifth of subjects had COVID-19 before their first dose of vaccination (n = 38, 22.6%). In terms of immunological responses, our investigations showed a high level of efficacy for the BNT162b2 mRNA vaccination as measured by S-RBD antibody concentrations: these were positive in 100% of participants 14 days after the second dose of the vaccine. It was also observed that employees with high S-RBD antibodies (>=433 BAU/mL) were more likely to be COVID-19 convalescents before receiving the first vaccine dose (p < 0.001). Conclusion: The BNT162b2 vaccine is safe and effective among HCWs. Vaccine adverse events occurred, but serious events were not observed. Moreover, the BNT162b2 vaccine is effective against symptomatic and severe COVID-19—none of the workers that acquired a SARS-CoV-2 infection after vaccination required hospitalization or medical care. We also observed higher immunological responses among COVID-19 convalescents. MDPI 2022-12-15 /pmc/articles/PMC9785047/ /pubmed/36560567 http://dx.doi.org/10.3390/vaccines10122158 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skrzat-Klapaczyńska, Agata
Kowalska, Justyna Dominika
Paciorek, Marcin
Puła, Joanna
Bieńkowski, Carlo
Krogulec, Dominika
Stengiel, Jarosław
Pawełczyk, Agnieszka
Perlejewski, Karol
Osuch, Sylwia
Radkowski, Marek
Horban, Andrzej
Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title_full Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title_fullStr Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title_full_unstemmed Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title_short Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center
title_sort higher immunological response after bnt162b2 vaccination among covid-19 convalescents—the data from the study among healthcare workers in an infectious diseases center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785047/
https://www.ncbi.nlm.nih.gov/pubmed/36560567
http://dx.doi.org/10.3390/vaccines10122158
work_keys_str_mv AT skrzatklapaczynskaagata higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT kowalskajustynadominika higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT paciorekmarcin higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT pułajoanna higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT bienkowskicarlo higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT krogulecdominika higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT stengieljarosław higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT pawełczykagnieszka higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT perlejewskikarol higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT osuchsylwia higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT radkowskimarek higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter
AT horbanandrzej higherimmunologicalresponseafterbnt162b2vaccinationamongcovid19convalescentsthedatafromthestudyamonghealthcareworkersinaninfectiousdiseasescenter